RezoluteRZLT
RZLT
About: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Employees: 59
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
5,461% more call options, than puts
Call options by funds: $1M | Put options by funds: $18K
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
20% more funds holding
Funds holding: 59 [Q3] → 71 (+12) [Q4]
13% more capital invested
Capital invested by funds: $187M [Q3] → $212M (+$24.8M) [Q4]
4.98% more ownership
Funds ownership: 69.61% [Q3] → 74.59% (+4.98%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
227%
upside
Avg. target
$11.50
318%
upside
High target
$14
409%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 29 / 171 met price target | 409%upside $14 | Buy Reiterated | 13 Feb 2025 |
JMP Securities Jason Butler 24% 1-year accuracy 10 / 42 met price target | 227%upside $9 | Market Outperform Maintained | 13 Feb 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?
Rezolute (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
3 weeks ago
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute.
Positive
Zacks Investment Research
1 month ago
Here's Why Rezolute (RZLT) Looks Ripe for Bottom Fishing
Rezolute (RZLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Positive
Seeking Alpha
1 month ago
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses.
Neutral
GlobeNewsWire
2 months ago
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
Positive
Zacks Investment Research
2 months ago
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
Neutral
GlobeNewsWire
2 months ago
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses
Neutral
GlobeNewsWire
2 months ago
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City.
Positive
Zacks Investment Research
3 months ago
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Rezolute (RZLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
3 months ago
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Charts implemented using Lightweight Charts™